← brief for 2026-08-17 · Slowing decline

Combination therapy of RAS inhibition and glucagon-like peptide-1 receptor agonist improves a marker of kidney fibrosis in people with type 2 diabetes.

Article C Peer reviewed Observational

Key takeaways

Researchers combined two drugs in people with type 2 diabetes: a blood pressure drug (a RAS inhibitor) and a GLP-1 drug. They measured a substance in the urine that tracks kidney scarring, called C3M. The combination lowered this marker, which may hint at less scarring. But this is only a marker, not proof the kidneys were protected, and it shows a link rather than cause.

Who did this work

Møller AL · Thöni S · Keller F · Sharifli S · Genovese F · Karsdal M · Rasmussen DGK · Mayer G

Source

Article · PubMed, fibrosis reversal · 2026 Aug 17
https://pubmed.ncbi.nlm.nih.gov/42605988/